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Background: Overexpression or mutated activation of Fibroblast growth factor receptor 3 (FGFR3) is involved in
the pathogenesis of many tumors. More and more studies focus on the potential usage of therapeutic antibodies
against FGFR3.
Results: In this study, a novel single-chain Fv (ScFv) against FGFR3 was prepared and characterized. To achieve
the soluble expression, ScFv was fused with Sumo (Small ubiquitin-related modiﬁer) by polymerase
chain reaction (PCR), and cloned into pET-20b. The recombinant bacteria were induced by 0.5 mM
Isopropyl-β-D-thiogalactopyranoside (IPTG) for 16 h at 20°C, and the supernatant liquid of Sumo-ScFv was
harvested and puriﬁed by Ni-NTA chromatography. After being cleaved by the Sumo protease, the
recombinant ScFv was released from the fusion protein, and further puriﬁed by Ni-NTA chromatography. The
purity of ScFv was shown to be higher than 95% and their yield reached 4 mg per liter of bacterial culture.
In vitro data showed that ScFv can signiﬁcantly attenuate FGF9-induced phosphorylation of FGFR3.
Conclusion: We provide a novel method to produce soluble expression and bioactive functions of ScFv in
Escherichia coli.© 2015 Pontiﬁcia Universidad Católica de Valparaíso. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Fibroblast growth factors (FGFs), a family of more than 20 known
members, play important roles in regulating cell proliferation,
differentiation and survival during embryo development and adult
stage [1]. FGF receptor (FGFR) mediated FGF-induced signaling
pathway. As one of FGFRs, FGFR3 was involved in many diseases,
especially cancer. Deregulation of FGFR3 was highlighted and deﬁned
in many types of cancer, such as multiple myeloma (MM) [2],
hepatocellular carcinoma [3] and bladder cancer [4]. Enhancing FGFR3
signaling promotes tumor growth, metastasis and resistance to drug.
Thus, FGFR3 has been considered as a novel therapy target for several
tumors, such as multiple myeloma [5] and bladder cancer [5,6].
Antibody is considered as one of themost effective strategies against
tumor antigens. The single chain Fv (ScFv), containing a variable heavy
chain (VH) and a variable light chain (VL) from monoclonal antibodyiao2400@jlu.edu.cn (Y. Xiao).
idad Católica de Valparaíso.
araíso. Production and hosting by Elhad been considered as a novel therapeutic antibody, and used to kill
tumors in recent years, such as anti-Her2 ScFv [7], anti-VEGF ScFv [8]
and anti-CA125 ScFv against epithelial ovarian cancer [9].
In recent ten years, many monoclonal antibodies or ScFvs against
FGFR3 have been reported on their anti-tumor activity in vitro and
in vivo. One kind of monoclonal antibody against FGFR3 inhibits
phosphorylation of FGFR3 and downstream signaling ERK activation in
MM cells [10]. ScFv against FGFR3 was shown to block the binding
of FGF9 and FGFR3, and inhibits proliferation of bladder cancer cell
line RT112 in vitro in a dose- and FGF-dependent manner [11].
Immunotoxin (ScFv-fused toxin) against FGFR3 was reported to
inhibit proliferation of bladder cancer cell line RT112 in vitro and
exhibited signiﬁcantly anti-tumor activity in RT112 tumor xenografts
by inducing cell apoptosis [12].
The Escherichia coli expression system is the principle choice to
get recombinant ScFv, however, recombinant ScFv often forms
inclusion body using traditional E. coli expression method [13,14].
To overcome these shortcomings, we chose a novel expression
system, small ubiquitin-related modiﬁer (Sumo) molecular partner.
Sumo covalently attached to other proteins to play roles of
post-translational modiﬁcations [15], including signiﬁcantly increasingsevier B.V. All rights reserved.
Fig. 1.Design and synthesis of Sumo-ScFv by PCR. (a) Sumo-ScFv was designed according to the schematic illustration. Firstly, Sumo-linkerwas created by PCR using P1 and P2. Secondly,
Sumo-ScFv was then synthesized by PCR using Sumo-linker and ScFv as templates, P1 and P3 as primers. The ﬁnal PCR product of Sumo-ScFv was shown in panel (b) and its molecular
weight is about 1070 bp.
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folding, and promoting protein solubility [16,17], so Sumo has become
an effective biotechnological tool as a fusion system in E. coli, by
which many recombinant proteins, such as FGF21 [18], pramlintide
[19], ScFv-9R [20], acquired better expression.
In the present study, we construct expression plasmid containing
Sumo and ScFv against FGFR3. The recombinant expression plasmid
was induced by IPTG in E. coli and puriﬁed by Ni-NTA. Further,
ScFv was released from Sumo-ScFv cleaved by Sumo enzyme. Our
results showed that Sumo is very helpful for promoting the soluble
expression of ScFv in E. coli, and the resulting recombinant bioactive
ScFv can be used for therapeutic applications and clinical diagnosis of
patients in the future.
2. Materials and methods
2.1. Reagents, enzymes, antibodies, bacterial strains
Prime STAR®GXL DNA Polymerase was purchased from TaKaRa
Company (Japan). Restriction enzymes NdeI and XhoI were provided
by NEB (England). Ni-NTA agarose was purchased from GE healthcare
(Sweden). Anti-His tag antibody was provided from Proteintech
(Chicago). p-FGFR3 (Tyr724) antibody was purchased from Santa
Cruz (USA). Anti-FGFR3 antibody was obtained from Abcam (USA).
Anti-beta-actin antibody was purchased from Cell Signaling (USA).
E. coli DH5α and E. coli BL21 (DE3) strains were obtained from
Invitrogen (USA). The E. coli expression plasmid pET-20b-SumoFig. 2. The inducible expression of recombinant Sumo-ScFv and soluble analysis by SDS-PAGE.
20°C, then the cell pellets were collected by centrifugation and protein was extracted by so
SDS-PAGE. Compared with negative control (NC) and without IPTG group, Sumo-ScFv highly
total bacteria, supernatant and precipitation of bacterial containing Sumo-ScFv.containing Sumo fragment was kept in Biochemistry lab, College of
Basic Medical Science, Jilin University. Dr. Qi Xiang from Jinan
University generously supplied us with the Sumo protease.
2.2. Design of fusion genes and constructions of pET-Sumo-ScFv
The ScFv genewas constructed in a VH-linker-VL format according
to the prior report [19] and US patent (8101721B2), and synthesized
by ZoonBio Biotechnology Co (China). The primers used for the
construction of fusion gene containing ScFv and Sumo fragment
were designed as follows: P1 (GGAATTCCATA TGCATCATCATCATCA
TCACG) was designed according to the 5′ terminal sequence of
Sumo fragment; P2 (5′CTCTGCTGCAGCTGCACCTGACCACC AATCTGTT
CTCTGT3′) contained 3′ terminal sequence of Sumo and 5′ terminal
sequence of ScFv. P3 (CCGCTCGAGTTACTGGCCCAGCACGGTCAGT)
primer was designed according to the 3′ terminal sequence of ScFv.
As shown in Fig. 1a, Sumo-linker was created by PCR using P1 and P2
as forward and reverse primers, using pET-20b-Sumo as a template.
PCR parameters consisted of 5 min of Prime STAR®GXL DNA
Polymerase activation at 98°C, followed by 30 cycles of denaturation
at 98°C for 10 s, annealing at 60°C for 15 s, extension at 68°C for 30 s,
and then a ﬁnal single extension at 68°C for 5 min.
Further, the Sumo-ScFv was generated by PCR, using P1 and P3 as
the forward and reverse primers, using Sumo-linker and ScFv as
templates. The fusion gene was digested with NdeI and XhoI, and
inserted into the pET-20b. Finally, the identiﬁed recombinant plasmid
was conﬁrmed by DNA sequencing (Sangon, Shanghai).Bacterial cells containing Sumo-ScFv were induced by 0.5 mM IPTG for 16 h induction at
nication and centrifugation. Both soluble and insoluble fractions were analyzed by 12%
expressed in recombinant bacteria by IPTG induction (panel (a)). The panel (b) showed
Fig. 4. The digestion of recombinant Sumo-ScFv by sumo protease and further puriﬁcation
through Ni-NTA. The puriﬁed Sumo-ScFv was digested by Sumo protease for 10 h at 4°C,
and then applied to the Ni-NTA column. The Sumo and Sumo protease containing
6His-tag were afﬁliated by Ni-NTA resin, only ScFv was eluted from the column when
washed off the resin with elution buffer. The results of digestion and puriﬁcation were
shown by SDS-PAGE.
Fig. 3. The puriﬁcation of recombinant Sumo-ScFv through Ni-NTA. The recombinant
protein of Sumo-ScFv supernatant shown was loaded on a Ni-NTA and washed with
different concentrations of imidazole. SDA-PAGE analysis showed the puriﬁcation of
recombinant Sumo-ScFv from eluant of 20 mM and 200 mM imidazole, as well as
Sumo-ScFv supernatant and balance elute.
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A single colony from E. coli BL21 (DE3) harboring pET-Sumo-ScFv
was grown overnight in the LB medium (1% peptone, 1% yeast extract,
and 0.5% sodium chloride, pH 7.0), and incubated in a shaker at 37°C.
A 3 ml aliquot of resulting culture was inoculated into 300 ml fresh LB
medium and incubated at 37°C and 220 rpm until OD600 was 0.6 to
0.8. Isopropyl-β-D-thiogalactopyranoside (IPTG) was added to 0.5 mM
ﬁnal concentration for 16 h induction at 20°C. The cell pellets were
collected by centrifugation and lysed by sonication. The supernatants
were harvested by centrifugation at 12,000 × g for 30 min at 4°C, and
the remaining pellets (insoluble fraction) containing inclusion bodies
were resuspended into an equal volume of lysis buffer. Both soluble
and insoluble fractions were analyzed by 12% SDS-PAGE [18].
2.4. Puriﬁcation of Sumo-ScFv
The cell lysate of Sumo-ScFvwas puriﬁed byNi-NTA chromatography.
The Ni-NTA resin was washed with wash buffer I (20 mM Tris–HCl,
pH 8.0) until OD280 of efﬂuent reached base line. The proteins without
6His-tag were eluted from the column with wash buffer II (20 mM
Tris–HCl containing 20 mM imidazole, pH 8.0). Finally, 6His-tagged
Sumo-ScFv protein was harvested from the column with elution buffer
(20 mM Tris–HCl containing 200 mM imidazole, pH 8.0). The purity of
Sumo-ScFv was assessed by SDS-PAGE and its concentration was
determined with BCA Protein Assay Kit.
2.5. Cleavage of Sumo from Sumo-ScFv and further puriﬁcation
The Sumo-ScFv protein was diluted to a concentration of 1 mgml-1.
10U Sumo protease were added to the dilution in salt buffer (20 mM
Tris–HCl, pH 7.0), and the mixture was incubated overnight at 4°C,
then the cleaved sample was applied to a Ni-NTA resin column. The
recombinant ScFv without His tag was washed directly, but Sumo and
Sumo protease containing His-tag were bound to the Ni-NTA resin
column. Finally, the recombinant ScFv was desalted overnight with
dialysis bag at 4°C.
2.6. Western blot analysis
The immunogenic activity of puriﬁed Sumo-ScFv was assayed by
Western blot. Total cellular protein was boiled in an equal volume of
sample loading buffer, a Tris–HCl buffer (pH 6.8) containing 20%
glycerol, 2.5% SDS, 10% β-mercaptoethanol and 0.005% bromophenol
blue. Protein samples were electrophoresed on 12% of SDS-PAGE,
and then electrophoretically transferred onto PVDF membrane. The
nonspeciﬁc binding of transferred membrane was blocked with 5%
non-fat milk powder overnight. The membrane was incubated with a
polyclonal anti-His tag antibody (1:1000), then washed and incubated
with a 1:1000 dilution of secondary HRP-conjugated antibody.
Immunoreactive bands were visualized using an ECL kit.
2.7. Mass spectrometry analysis
The speciﬁc band of ScFv from the SDS-PAGE gel was pooled
and analyzed by liquid chromatography–tandem mass spectrometry
(LC–MS/MS). This technical service was supported by Beijing Protein
Institute Co. Ltd.
2.8. Inhibition of FGFR3 signaling by ScFv in RT112 cells
RT112 cells were grown overnight in DMEM medium containing
10% FBS, 100 U ml-1 ampicillin and 100 U ml-1 streptomycin at 37°C
of cell incubator. Before stimulation, cells were ﬁrstly starved with
DMEM medium without FBS in the absence or presence of ScFv for
14 h, and then stimulated with 10 ng ml-1 FGF9 for 30 min. Then totalprotein from different treated RT112 cells was harvested and analyzed
by SDS-PAGE, and followed by Western blot with speciﬁc antibody
against p-FGFR3 and FGFR3. Beta-actin was detected as a loading
control.3. Results and discussion
3.1. Construction of pET-Sumo-ScFv expression plasmid
The gene sequence of ScFv was synthesized by Zoonbio Biotech Co.
(China) and its size is 738 bp. The fusion gene containing Sumo and
ScFv was generated according to the design of Fig. 1a by PCR. As
shown in Fig. 1b, the PCR product of Sumo-ScFv is about 1070 bp.
Further, Sumo-ScFv was double digested and cloned into pET-20b
plasmid. The Sumo-ScFv sequence which came from the recombinant
plasmid was conﬁrmed by DNA sequencing, and results showed that it
Fig. 5. The identiﬁcation of recombinant Sumo-ScFv and ScFv. The recombinant Sumo-ScFvwas detectedwith anti-His tag antibody byWestern blot (panel (a)). Both lane 1 and lane 2 are
recombinant Sumo-ScFv. As shown in panel (b), the ScFv whichwas removed Sumo by sumo proteasewas assayed byMass spectrometric method. The peptides in bold red highlymatch
with recombinant ScFv, in which its sequence coverage reaches 80%.
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gene can be found in GenBank (accession number KP405837).
3.2. Expression and puriﬁcation of Sumo-ScFv
E. coli cells harboring Sumo-ScFv were induced by 0.5 mM IPTG for
16 h at 20°C, then the cell pellets were harvested by centrifugation and
protein was extracted and separated by sonication and centrifugation.
The supernatants and precipitate were collected and performed to 12%
SDS-PAGE analysis. As shown in Fig. 2a, the expression of a 39 kDa
protein which is similar to the predicted size was induced by IPTG,
compared with negative control (blank plasmid) or recombinant
bacteria without IPTG induction.
To detect the soluble expression of recombinant Sumo-ScFv, the
supernatant and precipitate of cell lysate were both analyzed by
SDS-PAGE and the results showed Sumo-ScFv highly expressed in the
fraction of both supernatant and precipitate, but soluble fractions
(supernatant) exceed 50% of total target protein. Previous studies
showed that recombinant ScFv often forms inclusion body using
traditional E. coli expression method [13,14]. Our results suggested
that Sumo may be very helpful to promote soluble expression of
recombinant ScFv.
To acquire high purity recombinant protein, Ni-NTA was applied
to the puriﬁcation because 6His-tag was located in the N-terminal
of Sumo. Different concentrations of imidazole were tried to elute
the recombinant protein. The results showed that Sumo-ScFv was
efﬁciently eluted from Ni-NTA column using elusion buffer containingFig. 6. Inhibition of FGFR3 signaling pathway by ScFv-9R. RT112 cells were starved
with DMEM medium without FBS in the absence or presence of ScFv for 14 h, and
then stimulated with 10 ng ml-1 FGF9 for 30 min. Then total protein from different
treated RT112 cells was harvested and analyzed by SDS-PAGE, and followed by Western
blot with speciﬁc antibody against p-FGFR3 and FGFR3. Beta-actin was detected as a
loading control.200 mM imidazole. SDS-PAGE analysis showed that the purity of
Sumo-ScFv exceeds 90% (Fig. 3).
3.3. Further puriﬁcation and determination of ScFv after cleavage of Sumo
To cleave Sumo fragment from the fusion protein, the puriﬁed
Sumo-ScFv was digested by Sumo protease for 10 h at 4°C, and then
applied to the Ni-NTA column. The Sumo and Sumo protease
containing 6His-tag were afﬁliated by Ni-NTA resin, only ScFv was
eluted from the column when washed off the resin with elution buffer.
As shown in Fig. 4, SDS-PAGE analysis showed that more than 90%
recombinant Sumo-ScFv was efﬁciently cleaved by Sumo protease.
Because ScFv has no His tag, Sumo fragment from Sumo-ScFv could be
separated from ScFv by Ni-NTA column. SDS-PAGE analysis showed a
26 kDa band of ScFv, and its purity exceeds 95%. Since the 6His-tag and
start codon were put in the N-terminal of Sumo-ScFv, the recombinant
ScFv has a natural amino acid sequence without any tags after cleavage
of Sumo. This showed that Sumo expression system is a feasible
method to acquire natural recombinant protein without any tags.
3.4. Identiﬁcation of recombinant Sumo-ScFv and ScFv
To assay the authenticity of fusion protein, the immunoactivity of
puriﬁed Sumo-ScFv was performed with anti-his tag antibody by
Western blot due to 6His-tag designed in the N-terminal of Sumo. The
results revealed that Sumo-ScFv (Fig. 5a, lane 1 and lane 2) could
speciﬁcally react with anti-his tag antibody.
The immunoactivity of ScFv could not be performed because there
are no speciﬁc antibodies or antigens against recombinant ScFv. To
conﬁrm the authenticity of ScFv, ScFv was successfully identiﬁed by
Mass spectrometric method and detailed data was shown in Fig. 5b.
The results indicated that the data of score and sequence coverage
both match the amino acid sequence of ScFv.
3.5. ScFv speciﬁcally inhibits FGFR3 signaling in RT112 cells
To investigate whether ScFv has bioactivity against FGFR3 positive
cells, the bladder cancer RT112 cells which highly expressed FGFR3
were stimulated by FGF9 in the absence or presence of ScFv. The
phosphorylation of FGFR3 which represents receptor kinase activity was
detected by Western blot with speciﬁc antibody. The results showed
that FGF9 can stimulate FGFR3 phosphorylation signiﬁcantly and ScFv
efﬁciently attenuates FGF9-induced FGFR3 phosphorylation (Fig. 6). The
results also displayed that ScFv can speciﬁcally inhibit FGFR3 signaling
pathway by competing FGFR3 with FGFs. In Martínez-Torrecuadrada's
[11] study, several human ScFvs speciﬁcally bound FGFR3 were found
306 Z. Liu et al. / Electronic Journal of Biotechnology 18 (2015) 302–306and had competition activity with FGF9 by blocking FGFR3 activation and
inhibited RT112 cell proliferation. Next, we also deeply study ScFv
functions in blocking proliferation, migration and invasion of FGFR3
positive cancer cells. In recent years, tumor-speciﬁc immunoliposome
has become a novel delivery tool to carry siRNA drug or chemical drug
[21]. It's possible that our ScFv will be used to make immunoliposome
for tumor target therapy.
4. Conclusions
In this study, we report that the expression, puriﬁcation and
characterization of a novel ScFv antibody against FGFR3. This procedure
which fused with Sumo tag promotes the soluble expression of
recombinant ScFv and acquires natural and bioactive protein.
Conﬂict of interests
We declare that there is no conﬂict of interest regarding the
publication of this work.
Financial support
This work was supported by the Key Science & Technology Funding
of Jilin Province (20130206003YY), Bio-pharmaceutical grant from Jilin
Provincial Science & Technology Department (20130727041YY) and
National Natural Science Foundation of China (No. 81370640).
References
[1] Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in
cancer. Biochem J 2011;437:199–213. http://dx.doi.org/10.1042/bj20101603.
[2] Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, et al. Ectopic
expression of ﬁbroblast growth factor receptor 3 promotes myeloma cell proliferation
and prevents apoptosis. Blood 2000;95:992–8.
[3] Qiu WH, Zhou BS, Chu PG, Chen WG, Chung C, Shih J, et al. Over-expression of
ﬁbroblast growth factor receptor 3 in human hepatocellular carcinoma. World J
Gastroenterol 2005;11:5266–72.
[4] Di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in
bladder cancer: Past, present, and future challenges. Adv Urol 2012;2012:429213.
http://dx.doi.org/10.1155/2012/429213.
[5] Qing J, Du X, Chen Y, Chan P, Li H, Wu P. Antibody-based targeting of FGFR3 in
bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest
2009;119:1216–29. http://dx.doi.org/10.1172/JCI38017.
[6] Du X,Wang QR, Chan E, MerchantM, Liu J, French D, et al. FGFR3 stimulates stearoyl
CoA desaturase 1 activity to promote bladder tumor growth. Cancer Res 2012;72:
5843–55. http://dx.doi.org/10.1158/0008-5472.can-12-1329.[7] Akbari V, Mir Mohammad Sadeghi H, Jafrian-Dehkordi A, Abedi D, Chou CP.
Functional expression of a single-chain antibody fragment against human epidermal
growth factor receptor 2 (HER2) in Escherichia coli. J Ind Microbiol Biotechnol 2014;
41:947–56. http://dx.doi.org/10.1007/s10295-014-1437-0.
[8] Hosseini H, Rajabibazl M, Ebrahimizadeh W, Dehbidi GR. Inhibiting angiogenesis
with human single-chain variable fragment antibody targeting VEGF. Microvasc
Res 2015;97:13–8. http://dx.doi.org/10.1016/j.mvr.2014.09.002.
[9] Sharma SK, Suresh MR, Wuest FR. Improved soluble expression of a single-
chain antibody fragment in E. coli for targeting CA125 in epithelial ovarian
cancer. Protein Expr Purif 2014;102:27–37.
http://dx.doi.org/10.1016/j.pep.2014.07.007.
[10] Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S, et al. The inhibitory anti-FGFR3
antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006;107:
4039–46. http://dx.doi.org/10.1182/blood-2005-10-4179.
[11] Martínez-Torrecuadrada J, Cifuentes G, López-Serra P, Saenz P, Martínez A,
Casal JI. Targeting the extracellular domain of ﬁbroblast growth factor receptor
3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line
proliferation. Clin Cancer Res 2005;11:6280–90.
http://dx.doi.org/10.1158/1078-0432.ccr-05-0282.
[12] Martínez-Torrecuadrada JL, Cheung LH, López-Serra P, Barderas R, Cañamero M,
Ferreiro S, et al. Antitumor activity of ﬁbroblast growth factor receptor 3-speciﬁc
immunotoxins in a xenograft mouse model of bladder carcinoma is mediated
by apoptosis. Mol Cancer Ther 2008;7:862–73.
http://dx.doi.org/10.1158/1535-7163.mct-07-0394.
[13] Bu D, Zhou Y, Tang J, Jing F, Zhang W. Expression and puriﬁcation of a novel
therapeutic single-chain variable fragment antibody against BNP from inclusion
bodies of Escherichia coli. Protein Expr Purif 2013;92:203–7.
http://dx.doi.org/10.1016/j.pep.2013.10.002.
[14] Yuasa N, Koyama T, Fujita-Yamaguchi Y. Puriﬁcation and refolding of
anti-T-antigen single chain antibodies (scFvs) expressed in Escherichia
coli as inclusion bodies. Biosci Trends 2014;8:24–31.
http://dx.doi.org/10.5582/bst.8.24.
[15] Johnson ES. Protein modiﬁcation by SUMO. Annu Rev Biochem 2004;73:355–82.
[16] Butt TR, Edavettal SC, Hall JP, Mattern MR. SUMO fusion technology for difﬁcult-
to-express proteins. Protein Expr Purif 2005;43:1–9.
http://dx.doi.org/10.1016/j.pep.2005.03.016.
[17] Huang Y, Su Z, Li Y, Zhang Q, Cui L, Su Y, et al. Expression and puriﬁcation of
glutathione transferase-small ubiquitin-related modiﬁer-metallothionein fusion
protein and its neuronal and hepatic protection against D-galactose-induced
oxidative damage in mouse model. J Pharmacol Exp Ther 2009;329:469–78.
http://dx.doi.org/10.1124/jpet.108.149401.
[18] Wang H, Xiao Y, Fu L, Zhao H, Zhang Y, Wan X, et al. High-level expression
and puriﬁcation of soluble recombinant FGF21 protein by SUMO fusion in
Escherichia coli. BMC Biotechnol 2010;10:14.
http://dx.doi.org/10.1186/1472-6750-10-14.
[19] Hu H, Xiang Q, Liu H, Qu H, Tang X, Xiao X, et al. Expression, puriﬁcation,
and biological activity of the recombinant pramlintide precursor. Appl
Microbiol Biotechnol 2014;98:7837–44.
http://dx.doi.org/10.1007/s00253-014-5699-2.
[20] Zhang X, Xie J, Sun Y, Xu H, Du T, Liu Z, et al. High-level expression, puriﬁcation, and
characterization of bifunctional ScFv-9R fusion protein. Appl Microbiol Biotechnol
2014;98:5499–506. http://dx.doi.org/10.1007/s00253-014-5541-x.
[21] Gao J, Yu Y, Zhang Y, Song J, Chen H, Li W, et al. EGFR-speciﬁc PEGylated
immunoliposomes for active siRNA delivery in hepatocellular carcinoma. Biomaterials
2012;33:270–82. http://dx.doi.org/10.1016/j.biomaterials.2011.09.035.
